Femasys, Inc. (FEMY)
NASDAQ:FEMY
Want to see FEMY full AI Analyst Report?
Top Page
Femasys
(NASDAQ:FEMY)
Select Model
Select Model
Rating:45Neutral
Price Target:
$5.50
▲(653.42% Upside)
Action:Reiterated
Date:06/09/26
The score is primarily held back by very weak financial performance—large, persistent losses and heavy cash burn despite revenue growth—alongside a clearly bearish price trend. Valuation is difficult to support due to negative earnings, while recent corporate events provide only a modest positive offset.
Positive Factors
Revenue growth and commercial traction
Consistent multi-year revenue growth demonstrates early commercial uptake of FemVue and related consumables, indicating product-market fit in fertility diagnostics. Durable adoption by clinicians can produce repeat consumable revenue and support gradual scale, improving the path to sustainable operations if growth continues.
Negative Factors
Severe negative cash generation
Sustained large negative operating and free cash flow creates ongoing financing needs and constrains reinvestment. Over months this forces management to prioritize fundraising or cost cuts, increases dilution risk, and limits the firm’s ability to self-fund commercialization or regulatory activities absent a material revenue inflection.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and commercial traction
Consistent multi-year revenue growth demonstrates early commercial uptake of FemVue and related consumables, indicating product-market fit in fertility diagnostics. Durable adoption by clinicians can produce repeat consumable revenue and support gradual scale, improving the path to sustainable operations if growth continues.
Read all positive factors
Femasys (FEMY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.28M
Dividend YieldN/A
Average Volume (3M)87.32K
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue Growth39.88%
EPS Growth64.70%
CountryUS
Employees69
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-6.43
Shares Outstanding3,019,534
10 Day Avg. Volume80,598
30 Day Avg. Volume87,323
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.93
P/FCF Ratio-1.19
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue4.52
Enterprise Value/Gross Profit8.50
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$30.00Price Target Upside4009.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.53
Revenue Forecast (FY)$3.77M
Femasys Business Overview & Revenue Model
Company Description
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as F...
How the Company Makes Money
Femasys makes money primarily by selling and distributing its women’s health medical products to healthcare providers and clinical facilities. A key revenue stream is product revenue generated from the sale of FemVue and related consumables used i...
Femasys Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
16
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.29M | 1.63M | 1.07M | 1.21M | 1.18M |
| Gross Profit | 1.42M | 1.08M | 691.90K | 764.28K | 809.30K |
| EBITDA | -15.89M | -16.33M | -13.17M | -10.49M | -6.55M |
| Net Income | -18.63M | -18.82M | -14.25M | -11.39M | -7.54M |
Balance Sheet | |||||
| Total Assets | 20.72M | 12.45M | 27.76M | 16.90M | 28.58M |
| Cash, Cash Equivalents and Short-Term Investments | 9.27M | 3.45M | 21.72M | 12.96M | 24.78M |
| Total Debt | 4.70M | 7.44M | 6.70M | 543.72K | 990.21K |
| Total Liabilities | 14.85M | 10.14M | 9.40M | 1.65M | 2.24M |
| Stockholders Equity | 5.87M | 2.30M | 18.35M | 15.24M | 26.33M |
Cash Flow | |||||
| Free Cash Flow | -19.22M | -20.21M | -11.42M | -11.14M | -8.24M |
| Operating Cash Flow | -18.69M | -19.44M | -11.28M | -10.73M | -7.93M |
| Investing Cash Flow | -630.10K | -847.76K | -143.92K | -407.48K | -306.87K |
| Financing Cash Flow | 25.14M | 2.03M | 20.18M | -681.64K | 29.70M |
Femasys Technical Analysis
Negative
0.73
Price Trends
7.72
Negative
9.33
Negative
11.09
Negative
Market Momentum
-0.67
Positive
26.35
Positive
8.76
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Negative. The current price of 0.73 is below the 20-day moving average (MA) of 7.07, below the 50-day MA of 7.72, and below the 200-day MA of 11.09, indicating a bearish trend. The MACD of -0.67 indicates Positive momentum. The RSI at 26.35 is Positive, neither overbought nor oversold. The STOCH value of 8.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FEMY.
Femasys Risk Analysis
Femasys disclosed 78 risk factors in its most recent earnings report. Femasys reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Femasys Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $61.84M | -8.93 | -37.47% | ― | 64.18% | 28.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $34.49M | -7.01 | -166.28% | ― | 3.37% | 15.78% | |
46 Neutral | $20.66M | -3.29 | -8.13% | ― | 10.08% | 71.71% | |
45 Neutral | $14.28M | -1.27 | -258.08% | ― | 39.88% | 64.70% | |
45 Neutral | $6.63M | -1.44 | -55.33% | ― | 10.14% | 12.18% |
* Healthcare Sector Average
FEMY
Femasys
4.73
-12.27
-72.17%
RVP
Retractable Technologies
0.69
0.01
1.77%
MLSS
Milestone Scientific
0.39
-0.50
-56.29%
POCI
Precision Optics Corporation
5.65
0.80
16.49%
NXGL
NexGel Inc
0.57
-1.82
-76.32%
Femasys Corporate Events
Delistings and Listing ChangesShareholder MeetingsStock Split
Femasys Announces 1-for-20 Reverse Stock Split Implementation
Neutral
Jun 5, 2026
On June 5, 2026, Femasys Inc. implemented a 1-for-20 reverse stock split of its common shares, following stockholder authorization at a special meeting held on April 29, 2026. Every 20 shares of issued and outstanding common stock were automatical...
Business Operations and StrategyStock Split
Femasys Announces 1-for-20 Reverse Stock Split Initiative
Neutral
Jun 4, 2026
On June 4, 2026, Femasys Inc. announced a 1-for-20 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on June 5, 2026, with trading on a split-adjusted basis to begin on June 8, 2026 under the existing ticker FEMY and a n...
Business Operations and StrategyRegulatory Filings and Compliance
Femasys updates corporate presentation on women’s health portfolio
Positive
May 13, 2026
On May 13, 2026, Femasys Inc. posted an updated corporate slide presentation on its website, intended for use in ongoing meetings with investors, analysts and other stakeholders. The materials highlight the company’s diversified women’...
Private Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split
Femasys Shareholders Approve Reverse Split and Financing Plans
Neutral
Apr 29, 2026
At a special meeting of stockholders held on April 29, 2026, Femasys Inc. shareholders approved an amendment to the company’s certificate of incorporation authorizing a reverse stock split of its common shares at a ratio between 1-for-2 and ...
Business Operations and StrategyExecutive/Board Changes
Femasys Names John Canning as New Chief Operating Officer
Positive
Apr 1, 2026
On April 1, 2026, Femasys Inc. announced it had appointed veteran medical device executive John Canning as chief operating officer, effective March 30, 2026, as the company scales commercialization of its fertility and permanent birth control port...
Executive/Board ChangesPrivate Placements and Financing
Femasys Amends Financing Terms and Issues New Warrants
Neutral
Mar 20, 2026
Femasys Inc. amended its November 3, 2025 Securities Purchase Agreement with certain lenders on March 19, 2026, removing the share combination event adjustment from its senior secured convertible notes and associated warrants effective December 31...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.